SBBP

NASDAQ

Strongbridge Biopharma plc

SectorHealth CareIndustryMajor PharmaceuticalsIPO2015

News25/Ratings0

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that has completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.

Latest news

25 items

1569d13D/G
SEC Form SC 13D/A filed by Strongbridge Biopharma plc (Amendment)
SC 13D/A - Strongbridge Biopharma plc (0001634432) (Subject)
1569dINSIDER
SEC Form 4: Cdk Associates, L.L.C. disposed of 8,060,682 units of Ordinary Shares
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
1641d13D/G
SEC Form SC 13D/A filed by Strongbridge Biopharma plc (Amendment)
SC 13D/A - Strongbridge Biopharma plc (0001634432) (Subject)
1651dSEC
SEC Form 15-12B filed by Strongbridge Biopharma plc
15-12B - Strongbridge Biopharma plc (0001634432) (Filer)
1659dSEC
SEC Form EFFECT filed by Strongbridge Biopharma plc
EFFECT - Strongbridge Biopharma plc (0001634432) (Filer)
1659dSEC
SEC Form EFFECT filed by Strongbridge Biopharma plc
EFFECT - Strongbridge Biopharma plc (0001634432) (Filer)
1659dSEC
SEC Form EFFECT filed by Strongbridge Biopharma plc
EFFECT - Strongbridge Biopharma plc (0001634432) (Filer)
1660dINSIDER
SEC Form 4: Wilhoit Scott L. returned 109,510 units of Ordinary Shares to the company, closing all direct ownership in the company
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
1660dINSIDER
SEC Form 4: Kollender Richard S returned 234,229 units of Ordinary Shares to the company, closing all direct ownership in the company
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
1660dINSIDER
SEC Form 4: Cohen Fredric J. returned 160,408 units of Ordinary Shares to the company, decreasing direct ownership by 50% to 160,408 units
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
1660dINSIDER
SEC Form 4: Johnson John returned 610,092 units of Ordinary Shares to the company, closing all direct ownership in the company
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
1660dINSIDER
SEC Form 4: Steineger Hilde H returned 64,258 units of Ordinary Shares to the company, closing all direct ownership in the company
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
1660dINSIDER
SEC Form 4: Steen Marten returned 64,151 units of Ordinary Shares to the company
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
1660dINSIDER
SEC Form 4: Sherman Jeffrey W returned 64,258 units of Ordinary Shares to the company, closing all direct ownership in the company
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
1660dINSIDER
SEC Form 4: Kong Garheng returned 63,993 units of Ordinary Shares to the company, closing all direct ownership in the company
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
1660dINSIDER
SEC Form 4: Gill David N returned 78,058 units of Ordinary Shares to the company, closing all direct ownership in the company
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
1660dINSIDER
SEC Form 4: Long Stephen J returned 117,793 units of Ordinary Shares to the company, closing all direct ownership in the company
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
1661dINSIDER
SEC Form 4: Wilhoit Scott L. covered exercise/tax liability with 27,515 units of Ordinary Shares, decreasing direct ownership by 20% to 109,510 units
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
1661dINSIDER
SEC Form 4: Long Stephen J covered exercise/tax liability with 49,307 units of Ordinary Shares, decreasing direct ownership by 30% to 117,793 units
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
1661dINSIDER
SEC Form 4: Kollender Richard S covered exercise/tax liability with 64,791 units of Ordinary Shares, decreasing direct ownership by 22% to 234,229 units
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
1661dINSIDER
SEC Form 4: Cohen Fredric J. covered exercise/tax liability with 51,548 units of Ordinary Shares, decreasing direct ownership by 24% to 160,408 units
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
1661dINSIDER
SEC Form 4: Steen Marten covered exercise/tax liability with 17,763 units of Ordinary Shares
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
1661dINSIDER
SEC Form 4: Johnson John covered exercise/tax liability with 334,868 units of Ordinary Shares, decreasing direct ownership by 35% to 610,092 units
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
1661dINSIDER
SEC Form 4: Steineger Hilde H covered exercise/tax liability with 17,763 units of Ordinary Shares, decreasing direct ownership by 22% to 64,258 units
4 - Strongbridge Biopharma plc (0001634432) (Issuer)
1661dINSIDER
SEC Form 4: Sherman Jeffrey W covered exercise/tax liability with 17,763 units of Ordinary Shares, decreasing direct ownership by 22% to 64,258 units
4 - Strongbridge Biopharma plc (0001634432) (Issuer)